Literature DB >> 30526195

Current role of high dose chemotherapy in the management of multiple myeloma.

Morie A Gertz1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30526195      PMCID： PMC6548613          DOI： 10.1080/10428194.2018.1533131

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  13 in total

1.  Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.

Authors:  Mervi Putkonen; Veli Kairisto; Vesa Juvonen; Tarja-Terttu Pelliniemi; Auvo Rauhala; Maija Itälä-Remes; Kari Remes
Journal:  Eur J Haematol       Date:  2010-11       Impact factor: 2.997

2.  Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.

Authors:  Shaji K Kumar; Martha Q Lacy; Angela Dispenzieri; Francis K Buadi; Suzanne R Hayman; David Dingli; Francesca Gay; Shirshendu Sinha; Nelson Leung; William Hogan; S Vincent Rajkumar; Morie A Gertz
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

3.  Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma.

Authors:  Chintan Pandya; Shahrukh Hashmi; Nandita Khera; Morie A Gertz; Angela Dispenzieri; William Hogan; Mustaqeem Siddiqui; Katia Noyes; Shaji K Kumar
Journal:  Clin Transplant       Date:  2014-08-18       Impact factor: 2.863

4.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Authors:  Brian G M Durie; Antje Hoering; Muneer H Abidi; S Vincent Rajkumar; Joshua Epstein; Stephen P Kahanic; Mohan Thakuri; Frederic Reu; Christopher M Reynolds; Rachael Sexton; Robert Z Orlowski; Bart Barlogie; Angela Dispenzieri
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

5.  A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.

Authors:  Massimo Martino; Sabino Ciavarella; Simona De Summa; Letteria Russo; Nicola Meliambro; Lucrezia Imbalzano; Giuseppe Alberto Gallo; Tiziana Moscato; Giuseppe Messina; Anna Ferreri; Maria Cuzzola; Giuseppe Irrera; Virginia Naso; Michele Cimminiello; Giuseppe Console; Giacomo Loseto; Stefania Tommasi; Attilio Guarini
Journal:  Biol Blood Marrow Transplant       Date:  2017-10-13       Impact factor: 5.742

Review 6.  Advances in delivery of ambulatory autologous stem cell transplantation for multiple myeloma.

Authors:  Jack Khouri; Navneet S Majhail
Journal:  Curr Opin Support Palliat Care       Date:  2017-12       Impact factor: 2.302

7.  Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.

Authors:  M A Gertz; M Q Lacy; D J Inwards; D A Gastineau; A Tefferi; M G Chen; T E Witzig; P R Greipp; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

8.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

9.  Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.

Authors:  Neil C Dunavin; Lai Wei; Patrick Elder; Gary S Phillips; Don M Benson; Craig C Hofmeister; Sam Penza; Carli Greenfield; Karen S Rose; Gisele Rieser; Lisa Merritt; Jill Ketcham; Nyla Heerema; John C Byrd; Steven M Devine; Yvonne A Efebera
Journal:  Leuk Lymphoma       Date:  2012-12-31

10.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Authors:  Nikhil C Munshi; Herve Avet-Loiseau; Andy C Rawstron; Roger G Owen; J Anthony Child; Anjan Thakurta; Paul Sherrington; Mehmet Kemal Samur; Anna Georgieva; Kenneth C Anderson; Walter M Gregory
Journal:  JAMA Oncol       Date:  2017-01-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.